Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
04 May 2023 | Story Andre Damons | Photo Supplied
Prof Matsabisa Motlalepula
Prof Matsabisa Motlalepula, an African traditional medicine expert from the University of the Free State (UFS), will attend the first WHO Traditional Medicine Global Summit in India in August.

Prof Matsabisa Motlalepula, an African traditional medicine expert from the University of the Free State (UFS), will attend the first World Health Organisation (WHO) Traditional Medicine Global Summit in India in August after being invited to serve as a member of the Summit External Advisory Group for the WHO Traditional Medicine Global Summit (“Advisory Group”).

As chairperson of the WHO Regional Expert Advisory Committee on Traditional Medicine (REACT), Prof Motlalepula, the Director of the UFS Department of Pharmacology, has been nominated to serve as the Global Summit Advisory Group expert from the WHO to provide advice on themes, content, and format of sessions, and to provide reviews and recommendations to the Summit session coordinators and speakers at the Summit.

Summit will highlight success stories

The Advisory Group is comprised of nine members nominated across the six WHO regions and globally, with recognised expertise in traditional medicines as well as expertise on the Summit focus areas that include leadership and partnership, evidence and learning, data and regulation, biodiversity and sustainability, innovation and technology.

WHO will hold its Traditional Medicine Global Summit from August 17-18, 2023, in Gandhinagar, Gujarat, India, alongside the G20 health ministerial meeting. The Summit will be organised by the WHO Global Centre for Traditional Medicine collaborating closely with all WHO major offices. 

The Summit will highlight success stories in countries using traditional medicine across universal health coverage, the Sustainable Development Goals (SDGs), and Health for All. It will showcase game-changing advances in evidence, data, biodiversity and innovations that enable the safe, effective and equitable use of traditional medicine. The Summit will be a platform for all stakeholders of traditional medicine, including policymakers, practitioners, academics, private sector, civil society, community representatives, and others will discuss health and traditional medicines issues.

“It is always an honour and privilege for me to be asked to avail myself to the activities of such high-level United Nations bodies. I am humbled to be identified and nominated by WHO to be amongst the nine experts in the six WHO regions and globally. 

“I am very honoured and will do my utmost to deliver on the global mandate as well as stick to the terms of reference of my appointment to such a prestigious global summit. This shows the trust the WHO has in my capabilities, and this is good for the institution, the continent as well as the traditional health practitioners and scientists in this field of research,” says Prof Motlalepula. 

Endorsing well-researched traditional medicines

He says each time he sees the involvement of Africa in these international gatherings on traditional medicines, it marks another step toward the institutionalisation and global acceptance of African traditional medicines and medical practices in health systems. It further shows the growing role UFS is beginning to play in the global arena around traditional medicines.

According to him, he will, as always, push for WHO to be an example in support of traditional medicines and the participation of traditional health practitioners in its activities.

“I would seek from WHO to look into endorsing well-researched traditional medicine products and making them available in our health systems. Secondly, making recommendations for review of medicines regulatory authorities to reform and look favourably at traditional medicines product registration systems. I would advise on supporting continuous research into traditional medicines but more importantly for those products to be registered and put on the market.”

Prof Motlalepula says he has a few expectations, always working hard, dedicating his time and efforts to delivering what is expected, being part of a team and contributing to the overall team efforts. He expects positive resolutions moving forward the development and institutionalisation of traditional medicines, as well as a commitment to see the acceptance that the contribution of traditional medicines plays in the well-being of people and its formal contributions to universal health coverage and SDGs acknowledged. 

“I expect to hear about improved financial and political support for research and fast-tracking the manufacturing of well-researched, quality, safe and effective traditional medicines and their inclusion in national health systems. I expect to hear talk about integrated health that incorporates the application of traditional medicines in national health systems. I expect indeed a few positive things around the development of traditional medicine and serious commitment to supporting it.

“Given the scope of the work of the Advisory Group, it is very clear that the work is huge for the organisation, but I am ready for this,” says Prof Motlalepula.

The scope of work for the Advisory Group has been prepared and includes: 

  • Providing expert advice to WHO on the technical content and format of the sessions and exhibition for the WHO Traditional Medicine Global Summit;
  • Agreeing on technical review criteria with respect to thematic coherence across the Summit, strength of evidence and data, methodologies, global relevance and other considerations; 
  • Reviewing the proposed content of the Summit sessions and exhibitions using the technical review criteria and providing expert recommendations to ensure high-quality sessions;
  • Advising on the development of a journal series of papers related to the Global Summit using the agreed technical criteria to select the papers;
  • Providing expert inputs to Summit organisation meetings and multistakeholder consultations, as agreed with WHO;
  • Developing and sharing recommendations of the Summit advisory group with WHO and partners in a timely manner to inform the organisation of the Summit, as appropriate in alignment with the WHO conflict-of-interest declaration and Framework for Engagement with Non-State Actors (FENSA); and 
  • Developing an Advisory Group report advising WHO on key lessons and priority actions following the first WHO Traditional Medicine Global Summit.

News Archive

Higher than expected prevalence of dementia in South African urban black population
2010-09-22

 Prof. Malan Heyns and Mr Rikus van der Poel

Pilot research done by University of the Free State (UFS) indicates that the prevalence of dementia, of which Alzheimer’s disease is only one of the causes, is considerably higher than initially estimated. Clinical tests are now underway to confirm these preliminary findings.

To date it has been incorrectly assumed that dementia is less prevalent among urban black communities. This assumption is strongly disputed by the findings of the current study, which indicates a preliminary prevalence rate of approximately 6% for adults aged 65 years and older in this population group. Previous estimates for Southern Africa have been set at around 2,1%.

The research by the Unit for Professional Training and Services in the Behavioural Sciences (UNIBS) at the UFS and Alzheimer’s South Africa is part of the International 10/66 Dementia Research Group’s (10/66 DRG) initiative to establish the prevalence of dementia worldwide.

Mr Rikus van der Poel, coordinator of the local study, and Prof. Malan Heyns, Principal Investigator, say worldwide 66% of people with dementia live in low and middle income countries. It is expected that it will rise to more than 70% by 2040, and the socio-economic impact of dementia will increase accordingly within this period. 21 September marks World Alzheimer’s Day, and this year the focus is on the global economic impact of dementia. Currently, the world wide cost of dementia exceeds 1% of the total global GDP. If the global cost associated with dementia care was a company, it would be larger than Exxon-Mobil or Wal-Mart.

The researchers also say that of great concern is the fact that South Africa’s public healthcare system is essentially geared toward addressing primary healthcare needs, such as HIV/Aids and tuberculosis. The adult prevalence rate of HIV was 18,1% in 2007. According to UNAIDS figures more than 5,7 million people in South Africa are living with HIV/Aids, with an estimated annual mortality of 300 000. In many instances the deceased are young parents, with the result that the burden of childcare falls back on the elderly, and in many cases elderly grandparents suffering from dementia are left without children to take care of them. “These are but a few reasons that highlight the need for advocacy and awareness regarding dementia and care giving in a growing and increasingly urbanized population,” they say.

Low and middle income countries often lack epidemiological data to provide representative estimates of the regional prevalence of dementia. In general, epidemiological studies are challenging and expensive, especially in multi-cultural environments where the application of research protocols relies heavily on accurate language translations and successfully negotiated community access. Despite these challenges, the local researchers are keen to support advocacy and have joined the international effort to establish the prevalence of dementia through the 10/66 DRG.

The 10/66 DRG is a collective of researchers carrying out population-based research into dementia, non-communicable diseases and ageing in low and middle income countries. 10/66 refers to the two-thirds (66%) of people with dementia living in low and middle income countries, and the 10% or less of population-based research that has been carried out in those regions.

Since its inception in 1998, the 10/66 DRG has conducted population based surveys in 14 catchment areas in ten low and middle income countries, with a specific focus on the prevalence and impact of dementia. South Africa is one of seven LAMICs (low and medium income countries) where new studies have been conducted recently, the others being Puerto Rico, Peru, Mexico, Argentina, China and India.

Mr Van der Poel says participating researchers endeavour to conduct cross-sectional, comprehensive, one-phase surveys of all residents aged 65 and older within a geographically defined area. All centres share the same core minimum dataset with cross-culturally validated assessments (dementia diagnosis and subtypes, mental disorders, physical health, anthropometry, demographics, extensive non-communicable risk factor questionnaires, disability/functioning, health service utilization and caregiver strain).

The local pilot study, funded by Alzheimer’s South Africa, was rolled out through an existing community partnership, the Mangaung University of the Free State Community Partnership Programme (MUCPP).

According to Mr Van der Poel and Prof. Heyns, valuable insights have been gained into the myriad factors at play in establishing an epidemiological research project. The local community has responded positively and the pilot phase in and of itself has managed to promote awareness of the condition. The study has also managed to identify traditional and culture-specific views of dementia and dementia care. In addition, existing community-based networks are being strengthened, since part of the protocol will include the training and development of family caregivers within the local community in Mangaung.

“Like most developing economies, the South African population will experience continued urbanization during the next two decades, along with increased life expectancy. Community-based and residential care facilities for dementia are few and far between and government spending will in all probability continue to address the high demands associated with primary healthcare needs. These are only some of the reasons why epidemiological and related research is an important tool for assisting lobbyists, advocates and policymakers in promoting better care for those affected by dementia.”

Media Release
Issued by: Mangaliso Radebe
Assistant Director: Media Liaison
Tel: 051 401 2828
Cell: 078 460 3320
E-mail: radebemt@ufs.ac.za  
21 September 2010

 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept